Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1640, 2008-01, pp. : 23-23
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Nilotinib effective in imatinib-resistant/intolerant CML
Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. :
Access to resources
Recommend
Nilotinib, dasatinib or imatinib in CML: no clear winner
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :
Nilotinib better than imatinib, dasatinib for CML in Colombia
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 645, 2012-01 ,pp. :
Nilotinib favourable costs over dasatinib in CML . . .
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 605, 2010-01 ,pp. :
Verteporfin launched in the UK
Inpharma, Vol. 1, Iss. 1252, 2000-01 ,pp. :